2159 related articles for article (PubMed ID: 27069014)
1. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.
Pitt JM; Marabelle A; Eggermont A; Soria JC; Kroemer G; Zitvogel L
Ann Oncol; 2016 Aug; 27(8):1482-92. PubMed ID: 27069014
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.
Barnestein R; Galland L; Kalfeist L; Ghiringhelli F; Ladoire S; Limagne E
Oncoimmunology; 2022; 11(1):2120676. PubMed ID: 36117524
[TBL] [Abstract][Full Text] [Related]
3. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
Dzobo K
OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
[TBL] [Abstract][Full Text] [Related]
4. Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response.
Francis A; Venkatesh GH; Zaarour RF; Zeinelabdin NA; Nawafleh HH; Prasad P; Buart S; Terry S; Chouaib S
Crit Rev Immunol; 2018; 38(6):505-524. PubMed ID: 31002604
[TBL] [Abstract][Full Text] [Related]
5. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.
Li X; Wenes M; Romero P; Huang SC; Fendt SM; Ho PC
Nat Rev Clin Oncol; 2019 Jul; 16(7):425-441. PubMed ID: 30914826
[TBL] [Abstract][Full Text] [Related]
6. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
7. Multimodal Molecular Imaging of the Tumour Microenvironment.
Foray C; Barca C; Backhaus P; Schelhaas S; Winkeler A; Viel T; Schäfers M; Grauer O; Jacobs AH; Zinnhardt B
Adv Exp Med Biol; 2020; 1225():71-87. PubMed ID: 32030648
[TBL] [Abstract][Full Text] [Related]
8. The Janus Face of Tumor Microenvironment Targeted by Immunotherapy.
Buoncervello M; Gabriele L; Toschi E
Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484464
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
Saleh R; Elkord E
Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
[TBL] [Abstract][Full Text] [Related]
10. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
Bader JE; Voss K; Rathmell JC
Mol Cell; 2020 Jun; 78(6):1019-1033. PubMed ID: 32559423
[TBL] [Abstract][Full Text] [Related]
11. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy.
Schaaf MB; Garg AD; Agostinis P
Cell Death Dis; 2018 Jan; 9(2):115. PubMed ID: 29371595
[TBL] [Abstract][Full Text] [Related]
12. Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.
Zhang M; Kim JA; Huang AY
Front Immunol; 2018; 9():341. PubMed ID: 29535722
[TBL] [Abstract][Full Text] [Related]
13. Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.
Vedenko A; Panara K; Goldstein G; Ramasamy R; Arora H
Adv Exp Med Biol; 2020; 1277():143-158. PubMed ID: 33119871
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy.
Qiu Q; Lin Y; Ma Y; Li X; Liang J; Chen Z; Liu K; Huang Y; Luo H; Huang R; Luo L
Front Immunol; 2020; 11():612202. PubMed ID: 33488618
[TBL] [Abstract][Full Text] [Related]
15. Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies.
Faraj JA; Al-Athari AJH; Mohie SED; Kadhim IK; Jawad NM; Abbas WJ; Jalil AT
Med Oncol; 2022 Sep; 39(12):239. PubMed ID: 36175691
[TBL] [Abstract][Full Text] [Related]
16. Targeting the tumor microenvironment by immunotherapy: part 2.
Leibovici J; Itzhaki O; Huszar M; Sinai J
Immunotherapy; 2011 Nov; 3(11):1385-408. PubMed ID: 22053888
[TBL] [Abstract][Full Text] [Related]
17. Targeting innate sensing in the tumor microenvironment to improve immunotherapy.
Liu Z; Han C; Fu YX
Cell Mol Immunol; 2020 Jan; 17(1):13-26. PubMed ID: 31844141
[TBL] [Abstract][Full Text] [Related]
18. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
19. Chemopreventive agents targeting tumor microenvironment.
Sharma SH; Thulasingam S; Nagarajan S
Life Sci; 2016 Jan; 145():74-84. PubMed ID: 26679106
[TBL] [Abstract][Full Text] [Related]
20. Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.
Oliver AJ; Lau PKH; Unsworth AS; Loi S; Darcy PK; Kershaw MH; Slaney CY
Front Immunol; 2018; 9():70. PubMed ID: 29445373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
